Targeting Glioblastoma: Efficacy of Ruthenium-Based Drugs

IF 3.7 3区医学 Q2 CHEMISTRY, MEDICINAL

Chemical Research in Toxicology Pub Date : 2024-08-20 DOI:10.1021/acs.chemrestox.4c0018810.1021/acs.chemrestox.4c00188

Puthiyavalappil Rasin, Sravan Sangeeth Surendran, Karthik K S, Jebiti Haribabu and Anandaram Sreekanth*,

引用次数: 0

Abstract

Ruthenium compounds offer improved selectivity and fewer side effects compared to platinum-based drugs in glioblastoma treatment. Insights into their interactions with transferrin suggest targeted drug delivery, while photoactivated chemotherapy is a novel cytotoxic approach in tumor tissues.

Abstract Image

查看原文本刊更多论文

针对胶质母细胞瘤：钌基药物的疗效

与铂类药物相比，钌化合物在治疗胶质母细胞瘤方面具有更好的选择性和更少的副作用。对钌化合物与转铁蛋白相互作用的深入研究表明，钌化合物具有靶向给药作用，而光激活化疗则是肿瘤组织中的一种新型细胞毒疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemical Research in Toxicology 医学-毒理学

CiteScore

7.90

自引率

7.30%

发文量

215

审稿时长

3.5 months

期刊介绍： Chemical Research in Toxicology publishes Articles, Rapid Reports, Chemical Profiles, Reviews, Perspectives, Letters to the Editor, and ToxWatch on a wide range of topics in Toxicology that inform a chemical and molecular understanding and capacity to predict biological outcomes on the basis of structures and processes. The overarching goal of activities reported in the Journal are to provide knowledge and innovative approaches needed to promote intelligent solutions for human safety and ecosystem preservation. The journal emphasizes insight concerning mechanisms of toxicity over phenomenological observations. It upholds rigorous chemical, physical and mathematical standards for characterization and application of modern techniques.